ABSTRACT
The frequency and prognostic importance of subclinical myocardial necrosis after new device coronary intervention is not known. To identify the frequency of CPK-MB release after balloon and single new device angioplasty in native coronary arteries, we reviewed the course of 810 patients who underwent successful single lesion, native vessel angioplasty using balloon angioplasty (N=174), Gianturco-Roubin stent placement for suboptimal angioplasty results (N=31), Palmaz-Schatz stent deployment (N=320), directional coronary atherectomy (N=102), or rotational atherectomy (N=183). All patients had serial measurements of CPK-MB isoenzymes 6 and 18Ð24 hours after coronary intervention; absolute CPK-MB levels were determined by radioimmunoassay (normal assay < 4 ng/ml). CPK-MB isoenzymes were > 2 times normal (> 8 ng/dl) in 15.6% of procedures, > 3 times normal (³ 12 ng/ml) in 11.5% of procedures, > 4 times normal (³ 16 ng/ml) in 8.6% of procedures, and > 5 times normal (³ 20 ng/ml) in 7.7% of procedures. CPK-MB elevation > 2 times normal was more common in those undergoing directional atherectomy (20.8%) and Gianturco-Roubin stent placement (34,4%) than in those undergoing balloon angioplasty (11.7%). No significant differences were noted in patients undergoing rotational atherectomy (13.2%) or Palmaz-Schatz stent placement (15.6%) than in those undergoing balloon angioplasty. CPK-MB > 5 times normal occurred after 7.7% of procedures, but did not vary significantly among the devices used in this study. We conclude that CPK-MB elevations > 2 times normal are highest in patients undergoing directional coronary atherectomy and ÒbailoutÓ use of the Gianturco-Roubin stent. No significant differences in CPK-MB elevation were seen in patients undergoing balloon angioplasty, Palmaz-Schatz stent deployment, or rotational atherectomy. Identification of the prognostic importance of these CPK-MB elevations is currently under study.
